These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 19350463)

  • 1. Tenth Annual Phase I Clinical Trials Conference. Improving risk management and safety and increasing efficiency in phase I clinical trials. 10-11 February 2009, London, UK.
    Morgan S
    IDrugs; 2009 Apr; 12(4):220-2. PubMed ID: 19350463
    [No Abstract]   [Full Text] [Related]  

  • 2. Phase I clinical trials: overcoming barriers.
    Bates SE
    Clin Cancer Res; 2010 Mar; 16(6):1709. PubMed ID: 20215552
    [No Abstract]   [Full Text] [Related]  

  • 3. The elephant in the room.
    Nature; 2006 Dec; 444(7121):790. PubMed ID: 17167433
    [No Abstract]   [Full Text] [Related]  

  • 4. Better protection for human subjects is outcome of very early clinical trials.
    Maloney DM
    Hum Res Rep; 2006 May; 21(5):1-2. PubMed ID: 16832915
    [No Abstract]   [Full Text] [Related]  

  • 5. UK report recommends better planning for phase I drug trials.
    Mayor S
    BMJ; 2007 Mar; 334(7593):551. PubMed ID: 17363793
    [No Abstract]   [Full Text] [Related]  

  • 6. Opinion: Microdosing: safer clinical trials and fewer animal tests.
    Langley G; Farnaud S
    Bioanalysis; 2010 Mar; 2(3):393-5. PubMed ID: 21083249
    [No Abstract]   [Full Text] [Related]  

  • 7. Clinical development plan: N-Acetyl-l-cysteine.
    Kelloff GJ; Crowell JA; Boone CW; Steele VE; Lubet RA; Greenwald P; Alberts DS; Covey JM; Doody LA; Knapp GG
    J Cell Biochem Suppl; 1994; 20():63-73. PubMed ID: 7616754
    [No Abstract]   [Full Text] [Related]  

  • 8. Practical risk management in early phase clinical trials.
    Coates S; Täubel J; Lorch U
    Eur J Clin Pharmacol; 2019 Apr; 75(4):483-496. PubMed ID: 30569285
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Introduction of anticancer agents to phase I clinical trials].
    Shimoyama M
    Gan To Kagaku Ryoho; 1997 Jan; 24(2):246-55. PubMed ID: 9030238
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preparing for first-in-man studies: the challenges for translational immunology post-TGN1412.
    Dayan CM; Wraith DC
    Clin Exp Immunol; 2008 Feb; 151(2):231-4. PubMed ID: 18190459
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Clinical development of new drugs. Safety of clinical trials in healthy volunteers].
    Dal-Ré R
    Med Clin (Barc); 2016 Aug; 147(4):154-6. PubMed ID: 27157790
    [No Abstract]   [Full Text] [Related]  

  • 12. Britain adopts more stringent rules for phase I trials of high-risk compounds.
    Sinha G
    J Natl Cancer Inst; 2007 Jun; 99(12):915-7. PubMed ID: 17565146
    [No Abstract]   [Full Text] [Related]  

  • 13. TGN1412: the catalyst for change?
    Altern Lab Anim; 2006 Aug; 34(4):369-71. PubMed ID: 16969950
    [No Abstract]   [Full Text] [Related]  

  • 14. Hemodynamic surrogate end-points in phase I studies?
    De Mey C
    Int J Clin Pharmacol Ther; 1997 Apr; 35(4):175-9. PubMed ID: 9112140
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The strategy of combination phase I/II study].
    Murakami H; Ohe Y; Saijo N
    Gan To Kagaku Ryoho; 2000 Nov; 27(13):2151-4. PubMed ID: 11103251
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New designs for phase II trials: application to a trial of targeted therapies vs. chemotherapy in patients age > 60 with AML/high-risk MDS.
    Estey EH
    Ann Hematol; 2004; 83 Suppl 1():S94-6. PubMed ID: 15124692
    [No Abstract]   [Full Text] [Related]  

  • 17. Concentration-controlled trials. What does the future hold?
    Johnston A; Holt DW
    Clin Pharmacokinet; 1995 Feb; 28(2):93-9. PubMed ID: 7736691
    [No Abstract]   [Full Text] [Related]  

  • 18. New results will change the paradigm for phase I trials and drug approval.
    Chabner BA
    Oncologist; 2010; 15(10):1023-5. PubMed ID: 20930096
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An overview of the optimal planning, design, and conduct of phase I studies of new therapeutics.
    LoRusso PM; Boerner SA; Seymour L
    Clin Cancer Res; 2010 Mar; 16(6):1710-8. PubMed ID: 20215546
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current issues in phase I trials: new study designs and informed consent procedures.
    Cavalli F; Sessa C
    Ann Oncol; 1999; 10 Suppl 6():147-8. PubMed ID: 10676566
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.